Printer Friendly

VERIDIEN CORPORATION SEEKS INVESTMENT BANKING FIRM ASSISTANCE

    VERIDIEN CORPORATION SEEKS INVESTMENT BANKING FIRM ASSISTANCE
    SARASOTA, Fla., Nov. 21 /PRNewswire/ -- The Veridien Corporation, formerly Viral Control Technology, a health care firm with headquarters in Sarasota, Fla., announced today that it intends to retain a major investment banking firm to advise the company on joint ventures with major medical and dental distributors, and acquisition matters.
    Robert E. Yaw II, chief executive officer of Veridien, stated, "The company has taken this step in connection with its efforts to accelerate materially the manufacture and distribution of our products in the health care industry and to maximize the potential return on assets for our shareholders."
    Veridien plans to market a product line including a cold chemical sterilant and hospital-grade disinfectants.  The disinfectants are fast- acting, easy-to-use, low in toxicity and have received EPA registration. The cold chemical sterilant is the subject of a Premarket Notification Submission (510/K/ application) which is pending with the FDA.  The application claims that the sterilant kills spores, bacteria, viruses and tuberculosis in minutes at room temperature.  By contrast, products now on the market take from 6 to 10 hours.
    Veridien's products were developed by infection control authority Paul L. Simmons, chairman of Veridien, who for many years has consulted in the pharmaceutical, device and diagnostic industries.
    Patent protection is being sought for both products as well as eight additional products related to disinfection and sterilization and for use in the health care and food processing industries.
    Veridien President L. Randall Yates said, "We believe that the products we're developing will demonstrate great competitive advantage and be commercially successful.  Veridien's decision to retain an investment banking advisor will enable us to evaluate and negotiate various alternatives which should provide enhanced marketing support for our product line."
    Contract negotiations are underway with established distributors. In addition to hospitals and office-based medical practices, Veridien products will be used in the dental, veterinarian and food processing industries.
    Veridien is a Delaware corporation traded on the OTC Electronic Bulletin Board (VRAL).
    -0-                 11/21/91
    /CONTACT:  Brent Bullock, 813-922-1337, or Wayne Taylor, 813-923-5751, both of Veridien/
    (VRAL) CO:  Veridien Corporation ST:  Florida IN:  MTC SU: PS -- NY119 -- 6168 11/21/91 19:38 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 21, 1991
Words:363
Previous Article:THANKSGIVING HOLIDAY GAS PRICES REMAIN AT $1.19
Next Article:DEPT. OF HEALTH & HUMAN SERVICES: AGREEMENT REACHED ON MEDICAID FINANCING
Topics:


Related Articles
/C O R R E C T I O N -- VERIDIEN/
VERIDIEN CORPORATION STARTS 30-DAY CLINICAL TRIALS FOR NEW CHEMICAL COLD STERILANT
VERIDIEN SHAREHOLDERS AMEND COMPANY'S BYLAWS TO PERMIT GREATER FLEXIBILITY IN APPOINTMENT OF DIRECTORS
VERIDIEN CORPORATION REPORTS RESULTS
VERIDIEN ANNOUNCES OFFICIAL NOTICE OF PATENT ALLOWANCE FOR VIRAHOL 1
CLARK JOINS VERIDIEN CORPORATION AS SENIOR CONSULTANT TO THE CHAIRMAN
VERIDIEN EXPECTS FDA APPROVAL SOON ON HIV VIRUS-KILLING STERIHOL(TM)
VERIDIEN ACHIEVES PROFITABILITY AT CLOSE OF 1992
VERIDIEN PROJECTS FIRST QTR 2004 PROFIT.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters